Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...
HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...
SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- and long-acting insulins.
Insulin is an essential medicine that helps the body turn food into energy and regulate blood sugar levels for millions of people with diabetes nationwide. That makes access to insulin vital for ...
July 27, 2010 — The US Food and Drug Administration (FDA) has granted 510(k) clearance to market an insulin patch-pen (Finesse; Calibra Medical, Inc) for up to 3 days' use with rapid-acting insulin ...
Expert Rev Endocrinol Metab. 2010;5(4):507-516. The 'Summary of Product Characteristics' for BIAsp 30 has recently been changed to reflect data from the clinical trial program. These data showed that ...
The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...
The active ingredient in Fiasp is insulin aspart. (An active ingredient is what makes a drug work.) Fiasp is a biologic drug, which means it’s made from living cells. Fiasp comes as a liquid solution ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback